We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mobile Platform Offers Patients Ultrafast Genetic Diagnosis

By LabMedica International staff writers
Posted on 01 Jan 2024

Molecular diagnostics traditionally requires knowledge of handling complex equipment and sample preparation. More...

Now, a simple mobile platform for genetic diagnostics that is currently under development can be handled by healthcare professionals without any laboratory training.

Genomtec SA (Wrocław, Poland) is developing its flagship technological solution named Genomtec ID platform which will offer patients ultrafast mobile genetic diagnosis. The Genomtec ID platform is designed to facilitate diagnostic procedures on-site, including locations like public clinics, consulting rooms, hospitals, pharmacies, and emergency wards, eliminating the necessity for complex, time-consuming lab operations. The technology at the heart of Genomtec ID is the patented Streamlined Nucleic Acid Amplification Technology (SNAAT). This innovation ensures precise pathogen identification within 15 minutes, making it a rapid diagnostic solution. The Genomtec ID system combines the LAMP (loop-mediated isothermal amplification) method with microfluidics and a contactless photonic heating system. This integration allows for simultaneous isolation, purification, concentration, amplification, and detection of specific DNA or RNA fragments of pathogens, significantly speeding up the process while ensuring accuracy on par with or superior to conventional lab-based PCR methods.

One of the standout features of the SNAAT method is its capability for multiplexing, allowing for the simultaneous detection of multiple diagnostic targets on a microfluidic card. This means a single test can identify up to five pathogens at once. The use of a passive microfluidic card, devoid of embedded electronics or electric parts, for nucleic acid isolation, purification, and concentration, not only enhances the detection threshold for target nucleic acids but also reduces the manufacturing costs of disposable reaction cards. The robust diagnostic parameters offered by SNAAT, including sensitivity, specificity, and repeatability, are largely due to its resistance to common inhibitors found in biological samples like blood or drugs. This resistance makes SNAAT an innovative and reliable technology for point-of-care care testing (POCT), promising a new era of convenient and rapid diagnostics accessible to a broader range of healthcare settings.

Related Links:
Genomtec SA


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
PSA Test
Humasis PSA Card
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.